MEXC Exchange/Crypto Pulse/Sarah Chen
Sarah Chen

Sarah Chen

Nationality: Australia Bio: Sarah Chen specializes in DeFi protocols, smart contracts, and Layer-2 solutions. Based in Melbourne, she brings technical expertise and clear communication to complex blockchain topics. She holds a Bachelor's degree in Computer Science from the University of Melbourne and worked as a blockchain developer for three years before transitioning to technical writing. Her hands-on experience with Ethereum, Solana, and other platforms allows her to explain intricate concepts in accessible language. Since joining MEXC Learn in 2022, Sarah has focused on making blockchain technology understandable for all users, covering topics from DeFi yield farming to zero-knowledge proofs. Areas of Expertise: - DeFi Protocols - Smart Contract Analysis - Layer-2 Solutions - Blockchain Infrastructure - Protocol Security

Recent Articles

UMC Dividend Explained: ADS Payments, Withholding Tax and UMCON Treatment

UMC Dividend Explained: ADS Payments, Withholding Tax and UMCON Treatment

Summary United Microelectronics Corporation has a history of paying cash dividends to ordinary shareholders and UMC ADS holders. For the 2026 distribution cycle, shareholders approved a cash dividend

Why Does UMCON Track UMC? ADR Pricing, Dividends and Price Differences Explained

Why Does UMCON Track UMC? ADR Pricing, Dividends and Price Differences Explained

Summary UMCON is designed to provide total-return economic exposure linked to United Microelectronics Corporation’s NYSE-listed American Depositary Shares, ticker UMC. UMCON and UMC should generally

UMC Stock Price Prediction 2026–2030: Bull, Base and Bear Scenarios

UMC Stock Price Prediction 2026–2030: Bull, Base and Bear Scenarios

Summary UMC stock-price forecasts depend on semiconductor demand, mature-node pricing, factory utilization, dividend policy, currency movements, the Intel 12nm partnership and potential growth from

UMC Stock Analysis 2026: Foundry Demand, Mature Nodes, Intel 12nm and Dividends

UMC Stock Analysis 2026: Foundry Demand, Mature Nodes, Intel 12nm and Dividends

Summary United Microelectronics Corporation entered 2026 with a profitable semiconductor-foundry business, a strong position in mature and specialty process technologies, a growing 22nm product mix

UMC vs UMCON: ADR Ownership, Dividends, Trading Hours and Risks

UMC vs UMCON: ADR Ownership, Dividends, Trading Hours and Risks

Summary UMC and UMCON both provide exposure connected to United Microelectronics Corporation, but they are fundamentally different financial products. UMC is an American Depositary Share listed on

How to Trade UMCON/USDT on MEXC: A Step-by-Step Guide

How to Trade UMCON/USDT on MEXC: A Step-by-Step Guide

Summary UMCON is an Ondo tokenized stock designed to provide economic exposure linked to United Microelectronics Corporation’s New York Stock Exchange-listed American Depositary Shares, ticker UMC.

What Is United Microelectronics Stock (NYSE: UMC)? Business, ADR Structure and Risks

What Is United Microelectronics Stock (NYSE: UMC)? Business, ADR Structure and Risks

Summary United Microelectronics Corporation is a global semiconductor foundry headquartered in Hsinchu, Taiwan. Its ordinary shares trade on the Taiwan Stock Exchange under 2303, while its American

Why Does VRTXON Track VRTX? Pricing, Market Hours and Price Differences Explained

Why Does VRTXON Track VRTX? Pricing, Market Hours and Price Differences Explained

Summary VRTXON is designed to provide total-return economic exposure linked to Vertex Pharmaceuticals stock, VRTX. Its value should generally move in the same direction as VRTX, but the two prices

VRTX Stock Price Prediction 2026–2030: Bull, Base and Bear Scenarios

VRTX Stock Price Prediction 2026–2030: Bull, Base and Bear Scenarios

Summary VRTX stock price predictions depend on the durability of Vertex Pharmaceuticals’ cystic fibrosis franchise, growth from CASGEVY and JOURNAVX, the regulatory and commercial outcome for

VRTX Stock Analysis 2026: CF Franchise, CASGEVY, JOURNAVX, Pipeline and Valuation

VRTX Stock Analysis 2026: CF Franchise, CASGEVY, JOURNAVX, Pipeline and Valuation

Summary Vertex Pharmaceuticals enters the second half of 2026 with a strong cystic fibrosis franchise, growing contributions from ALYFTREK, CASGEVY and JOURNAVX, a potentially valuable kidney-disease